JPWO2020104635A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020104635A5 JPWO2020104635A5 JP2021526584A JP2021526584A JPWO2020104635A5 JP WO2020104635 A5 JPWO2020104635 A5 JP WO2020104635A5 JP 2021526584 A JP2021526584 A JP 2021526584A JP 2021526584 A JP2021526584 A JP 2021526584A JP WO2020104635 A5 JPWO2020104635 A5 JP WO2020104635A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- shp2
- subject
- shp2 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 5
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 5
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical group NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306558 | 2018-11-23 | ||
| EP18306558.0 | 2018-11-23 | ||
| PCT/EP2019/082180 WO2020104635A1 (en) | 2018-11-23 | 2019-11-22 | Use of shp2 inhibitors for the treatment of insulin resistance |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022509609A JP2022509609A (ja) | 2022-01-21 |
| JP2022509609A5 JP2022509609A5 (https=) | 2022-09-28 |
| JPWO2020104635A5 true JPWO2020104635A5 (https=) | 2022-09-28 |
| JP7454573B2 JP7454573B2 (ja) | 2024-03-22 |
Family
ID=64664217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526584A Active JP7454573B2 (ja) | 2018-11-23 | 2019-11-22 | インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220000869A1 (https=) |
| EP (1) | EP3883574A1 (https=) |
| JP (1) | JP7454573B2 (https=) |
| WO (1) | WO2020104635A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| EP4496566A1 (en) * | 2022-03-21 | 2025-01-29 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of shp2 inhibitors for inhibiting senescence |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117625770A (zh) * | 2022-08-26 | 2024-03-01 | 上海交通大学 | Ptpn11基因作为靶点在制备治疗药源性代谢综合征药物中的应用 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1062199A1 (en) | 1998-03-12 | 2000-12-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| CN100410236C (zh) | 2002-01-29 | 2008-08-13 | 雪兰诺实验室有限公司 | 作为蛋白酪氨酸磷酸酶调节剂的取代亚甲基酰胺衍生物 |
| US7399586B2 (en) * | 2002-05-23 | 2008-07-15 | Ceptyr, Inc. | Modulation of biological signal transduction by RNA interference |
| US20080058431A1 (en) | 2004-03-26 | 2008-03-06 | Gen-Sheng Feng | Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders |
| WO2007117699A2 (en) | 2006-04-07 | 2007-10-18 | University Of South Florida | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| EP3016652A4 (en) | 2013-07-03 | 2017-03-08 | Indiana University Research and Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
| US9932288B2 (en) | 2015-12-09 | 2018-04-03 | West Virginia University | Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent |
| NL2019390B1 (en) * | 2017-08-04 | 2019-02-21 | Univ Leiden | Screening Method |
| US11426422B2 (en) * | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
-
2019
- 2019-11-22 WO PCT/EP2019/082180 patent/WO2020104635A1/en not_active Ceased
- 2019-11-22 US US17/295,600 patent/US20220000869A1/en not_active Abandoned
- 2019-11-22 EP EP19805329.0A patent/EP3883574A1/en active Pending
- 2019-11-22 JP JP2021526584A patent/JP7454573B2/ja active Active
-
2024
- 2024-08-20 US US18/809,948 patent/US20250090529A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509609A5 (https=) | ||
| JPWO2020104635A5 (https=) | ||
| Rajagopal et al. | HOTAIR LncRNA: a novel oncogenic propellant in human cancer | |
| Savary et al. | The long noncoding RNA DNM3OS is a reservoir of FibromiRs with major functions in lung fibroblast response to TGF-β and pulmonary fibrosis | |
| JP2021531022A5 (https=) | ||
| Dubey et al. | RNA sequence and secondary structure participate in high-affinity CsrA–RNA interaction | |
| JP2008546390A5 (https=) | ||
| JP2013537423A5 (https=) | ||
| Azam et al. | Translation inhibition from a distance: the small RNA SgrS silences a ribosomal protein S1‐dependent enhancer | |
| JP2017509354A5 (https=) | ||
| JP2012136542A5 (https=) | ||
| Pant et al. | Genome-wide differential expression profiling of lncRNAs and mRNAs associated with early diabetic cardiomyopathy | |
| JP2010500291A5 (https=) | ||
| Wang et al. | LncRNA TUG1/miR-29c-3p/SIRT1 axis regulates endoplasmic reticulum stress-mediated renal epithelial cells injury in diabetic nephropathy model in vitro | |
| JP2011526482A5 (https=) | ||
| Stensløkken et al. | Expression of heat shock proteins in anoxic crucian carp (Carassius carassius): support for cold as a preparatory cue for anoxia | |
| Iglesias González et al. | The G protein-coupled receptor GPRC5A—a phorbol ester and retinoic acid-induced orphan receptor with roles in cancer, inflammation, and immunity | |
| Li et al. | Non-coding RNAs regulate autophagy in kidney disease: friend or foe? | |
| Sousa et al. | Bacterial Small RNAs: Diversity of Structure and Function | |
| JP2018520150A5 (https=) | ||
| CN114585738A (zh) | 用于治疗血小板减少症的核酸分子及其应用 | |
| JP2019525903A5 (https=) | ||
| EP3317412A1 (en) | Methods and pharmaceutical compositions for the treatment of cystic fibrosis | |
| JP2009518438A5 (https=) | ||
| JP2006089475A5 (https=) |